Citigroup
TTNP

Citigroup’s Titan Pharmaceuticals TTNP Stock Holding History

Citigroup’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-88
Closed -$1K – 6328
2022
Q2 		$1K Buy
+88
New +$1.1K ﹤0.01% 6100
2017
Q3 		– Hold
0
– – – 7443
2017
Q2 		– Hold
0
– – – 7484
2017
Q1 		– Sell
-5
Closed -$70.3K – 7343
2016
Q4 		$76K Hold
5
– – ﹤0.01% 5932
2016
Q3 		$98K Buy
5
+4
+400% +$77.7K ﹤0.01% 5221
2016
Q2 		$10K Buy
+1
New +$21.3K ﹤0.01% 6557

Other funds holding TTNP

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's TTNP Position: Q3 2022 in Review

Citigroup sold out of Titan Pharmaceuticals (TTNP) in Q3 2022, closing a stake of 88 shares — an estimated $1K sold.

Citigroup first reported a position in TTNP in Q2 2016 and held it in 4 quarters. The position peaked at $98K in Q3 2016. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2022.

  • Citigroup reported no remaining Titan Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 88 Titan Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • Citigroup first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Citigroup's Titan Pharmaceuticals position peaked at $98K in Q3 2016.
  • 18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.